Gilead Sciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. 

CEO
Daniel P. O'Day
CEODaniel P. O'Day
Employees
17,000
Employees17,000
Headquarters
Foster City, California
HeadquartersFoster City, California
Founded
1987
Founded1987
Employees
17,000
Employees17,000

GILD Key Statistics

Market cap
206.87B
Market cap206.87B
Price-Earnings ratio
-53.67
Price-Earnings ratio-53.67
Dividend yield
1.92%
Dividend yield1.92%
Average volume
5.51M
Average volume5.51M
High today
$169.16
High today$169.16
Low today
$166.14
Low today$166.14
Open price
$168.72
Open price$168.72
Volume
684.16K
Volume684.16K
52 Week high
$176.58
52 Week high$176.58
52 Week low
$116.88
52 Week low$116.88

Stock Snapshot

Gilead Sciences(GILD) stock is priced at $166.78, giving the company a market capitalization of 206.87B. It carries a P/E multiple of -53.67 and pays a dividend yield of 1.92%.

During the trading session on 2026-11-19, Gilead Sciences(GILD) shares reached a daily high of $169.16 and a low of $166.14. At a current price of $166.78, the stock is +0.4% higher than the low and still -1.4% under the high.

Trading activity shows a volume of 684.16K, compared to an average daily volume of 5.51M.

The stock's 52-week range extends from a low of $116.88 to a high of $176.58.

The stock's 52-week range extends from a low of $116.88 to a high of $176.58.

GILD News

Simply Wall St 16m
Gilead Sciences Has Investors Looking Closer, What Is Behind The Attention?

Gilead Sciences (GILD) just put its HIV prevention portfolio in the spotlight after new PURPOSE 5 trial data showed that twice-yearly lenacapavir kept more peop...

Gilead Sciences Has Investors Looking Closer, What Is Behind The Attention?
Simply Wall St 1d
How Investors Are Reacting To Gilead Sciences Strong HIV Trial Data - Simply Wall St

...

How Investors Are Reacting To Gilead Sciences Strong HIV Trial Data - Simply Wall St
Zacks 1d
Gilead Sciences, Inc. is Attracting Investor Attention: Here is What You Should Know

Gilead Sciences (GILD Quick QuoteGILD - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some...

Gilead Sciences, Inc. is Attracting Investor Attention: Here is What You Should Know

Analyst ratings

76%

of 29 ratings
Buy
75.9%
Hold
20.7%
Sell
3.4%

More GILD News

Benzinga 2d
Gilead Partners With Generic Manufacturers to Boost Future Access to Experimental Ebola Prevention Drug

Gilead Sciences Inc. (NASDAQ:GILD) said Monday it signed royalty-free voluntary licensing agreements with three generic drugmakers to support potential future a...

Gilead Partners With Generic Manufacturers to Boost Future Access to Experimental Ebola Prevention Drug
The Motley Fool 3d
These 3 Dividend Stocks Have Crushed the Market This Year. Here’s Why They Are Still Buys

Artificial intelligence (AI) stocks continue dominating headlines on Wall Street. That probably won't change anytime soon. But investors shouldn't be so distrac...

These 3 Dividend Stocks Have Crushed the Market This Year. Here’s Why They Are Still Buys
TipRanks 3d
Gilead signs royalty-free licensing pacts over antiviral obeldesivir

Gilead (GILD) Sciences announced that it has signed royalty-free voluntary licensing agreements with three generic manufacturers to support potential future acc...

24/7 Wall St. 3d
How Retirees Can Turn $50,000 Into Passive Income With These 4 Dividend Stocks

It sounds nuts, but SoFi is giving new Active Invest users up to $1,000 in stock for a limited time, and all it takes is a $50 deposit to get started. See for y...

How Retirees Can Turn $50,000 Into Passive Income With These 4 Dividend Stocks
Simply Wall St 4d
Gilead Sciences Wins Bixlenvo Approval With Another FDA Call Due In December

Gilead Sciences (NasdaqGS:GILD) received FDA approval for Bixlenvo, a bictegravir and lenacapavir regimen for HIV treatment. The firm has a Biologics License A...

Gilead Sciences Wins Bixlenvo Approval With Another FDA Call Due In December
TipRanks 5d
Gilead Sciences Earnings Call Signals Broad Growth Momentum

Gilead Sciences ((GILD)) has held its Q3 earnings call. Read on for the main highlights of the call. Gilead Sciences delivered a strongly positive third-quarte...

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.